1
|
Chatterjee P, Zetterberg H, Goozee K, Lim CK, Jacobs KR, Ashton NJ, Hye A, Pedrini S, Sohrabi HR, Shah T, Asih PR, Dave P, Shen K, Taddei K, Lovejoy DB, Guillemin GJ, Blennow K, Martins RN. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. J Neuroinflammation 2019; 16:186. [PMID: 31601232 PMCID: PMC6788092 DOI: 10.1186/s12974-019-1567-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Accepted: 08/29/2019] [Indexed: 12/13/2022] Open
Abstract
Background Blood markers indicative of neurodegeneration (neurofilament light chain; NFL), Alzheimer’s disease amyloid pathology (amyloid-β; Aβ), and neuroinflammation (kynurenine pathway; KP metabolites) have been investigated independently in neurodegenerative diseases. However, the association of these markers of neurodegeneration and AD pathology with neuroinflammation has not been investigated previously. Therefore, the current study examined whether NFL and Aβ correlate with KP metabolites in elderly individuals to provide insight on the association between blood indicators of neurodegeneration and neuroinflammation. Methods Correlations between KP metabolites, measured using liquid chromatography and gas chromatography coupled with mass spectrometry, and plasma NFL and Aβ concentrations, measured using single molecule array (Simoa) assays, were investigated in elderly individuals aged 65–90 years, with normal global cognition (Mini-Mental State Examination Score ≥ 26) from the Kerr Anglican Retirement Village Initiative in Ageing Health cohort. Results A positive correlation between NFL and the kynurenine to tryptophan ratio (K/T) reflecting indoleamine 2,3-dioxygenase activity was observed (r = .451, p < .0001). Positive correlations were also observed between NFL and kynurenine (r = .364, p < .0005), kynurenic acid (r = .384, p < .0001), 3-hydroxykynurenine (r = .246, p = .014), anthranilic acid (r = .311, p = .002), and quinolinic acid (r = .296, p = .003). Further, significant associations were observed between plasma Aβ40 and the K/T (r = .375, p < .0005), kynurenine (r = .374, p < .0005), kynurenic acid (r = .352, p < .0005), anthranilic acid (r = .381, p < .0005), and quinolinic acid (r = .352, p < .0005). Significant associations were also observed between plasma Aβ42 and the K/T ratio (r = .215, p = .034), kynurenic acid (r = .214, p = .035), anthranilic acid (r = .278, p = .006), and quinolinic acid (r = .224, p = .027) in the cohort. On stratifying participants based on their neocortical Aβ load (NAL) status, NFL correlated with KP metabolites irrespective of NAL status; however, associations between plasma Aβ and KP metabolites were only pronounced in individuals with high NAL while associations in individuals with low NAL were nearly absent. Conclusions The current study shows that KP metabolite changes are associated with biomarker evidence of neurodegeneration. Additionally, the association between KP metabolites and plasma Aβ seems to be NAL status dependent. Finally, the current study suggests that an association between neurodegeneration and neuroinflammation manifests in the periphery, suggesting that preventing cytoskeleton cytotoxicity by KP metabolites may have therapeutic potential. Electronic supplementary material The online version of this article (10.1186/s12974-019-1567-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Pratishtha Chatterjee
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia.,School of Medical Health and Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.,Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.,Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.,UK Dementia Research Institute at UCL, London, UK
| | - Kathryn Goozee
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia.,School of Medical Health and Sciences, Edith Cowan University, Joondalup, WA, Australia.,KaRa Institute of Neurological Disease, Sydney, Macquarie Park, NSW, Australia.,Clinical Research Department, Anglicare, Sydney, Castle Hill, NSW, Australia.,School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australia
| | - Chai K Lim
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | - Kelly R Jacobs
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | - Nicholas J Ashton
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.,Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London, London, UK.,NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia, South London and Maudsley NHS Foundation, London, UK.,Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Abdul Hye
- Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London, London, UK.,NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia, South London and Maudsley NHS Foundation, London, UK
| | - Steve Pedrini
- School of Medical Health and Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Hamid R Sohrabi
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia.,School of Medical Health and Sciences, Edith Cowan University, Joondalup, WA, Australia.,KaRa Institute of Neurological Disease, Sydney, Macquarie Park, NSW, Australia.,Australian Alzheimer's Research Foundation, Nedlands, WA, Australia
| | - Tejal Shah
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia.,School of Medical Health and Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation, Nedlands, WA, Australia
| | - Prita R Asih
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | - Preeti Dave
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia.,Clinical Research Department, Anglicare, Sydney, Castle Hill, NSW, Australia
| | - Kaikai Shen
- Australian eHealth Research Centre, CSIRO, Floreat, WA, Australia
| | - Kevin Taddei
- School of Medical Health and Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation, Nedlands, WA, Australia
| | - David B Lovejoy
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | - Gilles J Guillemin
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.,Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Ralph N Martins
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia. .,School of Medical Health and Sciences, Edith Cowan University, Joondalup, WA, Australia. .,KaRa Institute of Neurological Disease, Sydney, Macquarie Park, NSW, Australia. .,School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australia. .,Australian Alzheimer's Research Foundation, Nedlands, WA, Australia. .,The Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia. .,School of Medical and Health Sciences, Edith Cowan University, Ralph & Patricia Sarich Neuroscience Research Institute, 8 Verdun Street, Nedlands, WA, 6009, Australia.
| |
Collapse
|
3
|
Dengler-Crish CM, Smith MA, Inman DM, Wilson GN, Young JW, Crish SD. Anterograde transport blockade precedes deficits in retrograde transport in the visual projection of the DBA/2J mouse model of glaucoma. Front Neurosci 2014; 8:290. [PMID: 25278826 PMCID: PMC4166356 DOI: 10.3389/fnins.2014.00290] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Accepted: 08/27/2014] [Indexed: 01/30/2023] Open
Abstract
Axonal transport deficits have been reported as an early pathology in several neurodegenerative disorders, including glaucoma. However, the progression and mechanisms of these deficits are poorly understood. Previous work suggests that anterograde transport is affected earlier and to a larger degree than retrograde transport, yet this has never been examined directly in vivo. Using combined anterograde and retrograde tract tracing methods, we examined the time-course of anterograde and retrograde transport deficits in the retinofugal projection in pre-glaucomatous (3 month-old) and glaucomatous (9–13 month old) DBA/2J mice. DBA/2J-Gpnmb+ mice were used as a control strain and were shown to have similar retinal ganglion cell densities as C57BL/6J control mice—a strain commonly investigated in the field of vision research. Using cholera toxin-B injections into the eye and FluoroGold injections into the superior colliculus (SC), we were able to measure anterograde and retrograde transport in the primary visual projection. In DBA/2J, anterograde transport from the retina to SC was decreased by 69% in the 9–10 month-old age group, while retrograde transport was only reduced by 23% from levels seen in pre-glaucomatous mice. Despite this minor reduction, retrograde transport remained largely intact in these glaucomatous age groups until 13-months of age. These findings indicate that axonal transport deficits occur in semi-functional axons that are still connected to their brain targets. Structural persistence as determined by presence of estrogen-related receptor beta label in the superficial SC was maintained beyond time-points where reductions in retrograde transport occurred, also supporting that transport deficits may be due to physiological or functional abnormalities as opposed to overt structural loss.
Collapse
Affiliation(s)
- Christine M Dengler-Crish
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University Rootstown, OH, USA ; Department of Anatomy and Neurobiology, Northeast Ohio Medical University Rootstown, OH, USA
| | - Matthew A Smith
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University Rootstown, OH, USA ; Integrated Pharmaceutical Medicine Graduate Program, Northeast Ohio Medical University Rootstown, OH, USA
| | - Denise M Inman
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University Rootstown, OH, USA
| | - Gina N Wilson
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University Rootstown, OH, USA ; Biomedical Sciences Graduate Program, Kent State University Kent, OH, USA
| | - Jesse W Young
- Department of Anatomy and Neurobiology, Northeast Ohio Medical University Rootstown, OH, USA
| | - Samuel D Crish
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University Rootstown, OH, USA
| |
Collapse
|
5
|
Samantaray S, Knaryan VH, Shields DC, Banik NL. Critical role of calpain in spinal cord degeneration in Parkinson's disease. J Neurochem 2013; 127:880-90. [PMID: 23875735 DOI: 10.1111/jnc.12374] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2013] [Revised: 06/26/2013] [Accepted: 07/05/2013] [Indexed: 11/29/2022]
Abstract
While multiple molecular mechanisms contribute to midbrain nigrostriatal dopaminergic degeneration in Parkinson's disease (PD), the mechanism of damage in non-dopaminergic sites within the central nervous system, including the spinal cord, is not well-understood. Thus, to understand the comprehensive pathophysiology underlying this devastating disease, postmortem spinal cord tissue samples (cervical, thoracic, and lumbar segments) from patients with PD were analyzed compared to age-matched normal subjects or Alzheimer's disease for selective molecular markers of neurodegeneration and inflammation. Distal axonal degeneration, relative abundance of both sensory and motor neuron death, selective loss of ChAT(+) motoneurons, reactive astrogliosis, microgliosis, increased cycloxygenase-2 (Cox-2) expression, and infiltration of T cells were observed in spinal cord of PD patients compared to normal subjects. Biochemical analyses of spinal cord tissues revealed associated inflammatory and proteolytic events (elevated levels of Cox-2, expression and activity of μ- and m-calpain, degradation of axonal neurofilament protein, and concomitantly low levels of endogenous inhibitor - calpastatin) in spinal cord of PD patients. Thus, pathologically upregulated calpain activity in spinal cords of patients with PD may contribute to inflammatory response-mediated neuronal death, leading to motor dysfunction. We proposed calpain over-activation and calpain-calpastatin dysregulation driving in a cascade of inflammatory responses (microglial activation and T cell infiltration) and degenerative pathways culminating in axonal degeneration and neuronal death in spinal cord of Parkinson's disease patients. This may be one of the crucial mechanisms in the degenerative process.
Collapse
Affiliation(s)
- Supriti Samantaray
- Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 309 CSB, P.O. Box 250606, Charleston, SC, 29425, USA
| | - Varduhi H Knaryan
- Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 309 CSB, P.O. Box 250606, Charleston, SC, 29425, USA
| | - Donald C Shields
- Department of Neurosurgery, The George Washington University, 2150 Pennsylvania Avenue, NW, Suite 7-420, Washington, DC, 20037, USA
| | - Naren L Banik
- Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 309 CSB, P.O. Box 250606, Charleston, SC, 29425, USA
| |
Collapse
|
6
|
Holmgren A, Bouhy D, De Winter V, Asselbergh B, Timmermans JP, Irobi J, Timmerman V. Charcot-Marie-Tooth causing HSPB1 mutations increase Cdk5-mediated phosphorylation of neurofilaments. Acta Neuropathol 2013; 126:93-108. [PMID: 23728742 PMCID: PMC3963106 DOI: 10.1007/s00401-013-1133-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2013] [Revised: 05/03/2013] [Accepted: 05/21/2013] [Indexed: 01/21/2023]
Abstract
Mutations in the small heat shock protein HSPB1 (HSP27) are a cause of axonal Charcot-Marie-Tooth neuropathy (CMT2F) and distal hereditary motor neuropathy. To better understand the effect of mutations in HSPB1 on the neuronal cytoskeleton, we stably transduced neuronal cells with wild-type and mutant HSPB1 and investigated axonal transport of neurofilaments (NFs). We observed that mutant HSPB1 affected the binding of NFs to the anterograde motor protein kinesin, reducing anterograde transport of NFs. These deficits were associated with an increased phosphorylation of NFs and cyclin-dependent kinase Cdk5. As Cdk5 mediates NF phosphorylation, inhibition of Cdk5/p35 restored NF phosphorylation level, as well as NF binding to kinesin in mutant HSPB1 neuronal cells. Altogether, we demonstrate that HSPB1 mutations induce hyperphosphorylation of NFs through Cdk5 and reduce anterograde transport of NFs.
Collapse
Affiliation(s)
- Anne Holmgren
- Department of Molecular Genetics, VIB and University of Antwerp, 2610 Antwerpen, Belgium
- Laboratory of Neurogenetics, Institute Born-Bunge, 2610 Antwerpen, Belgium
| | - Delphine Bouhy
- Department of Molecular Genetics, VIB and University of Antwerp, 2610 Antwerpen, Belgium
- Laboratory of Neurogenetics, Institute Born-Bunge, 2610 Antwerpen, Belgium
| | - Vicky De Winter
- Department of Molecular Genetics, VIB and University of Antwerp, 2610 Antwerpen, Belgium
- Laboratory of Neurogenetics, Institute Born-Bunge, 2610 Antwerpen, Belgium
| | - Bob Asselbergh
- Department of Molecular Genetics, VIB and University of Antwerp, 2610 Antwerpen, Belgium
- Laboratory of Neurogenetics, Institute Born-Bunge, 2610 Antwerpen, Belgium
| | - Jean-Pierre Timmermans
- Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, University of Antwerp, 2020 Antwerpen, Belgium
| | - Joy Irobi
- Department of Molecular Genetics, VIB and University of Antwerp, 2610 Antwerpen, Belgium
- Laboratory of Neurogenetics, Institute Born-Bunge, 2610 Antwerpen, Belgium
| | - Vincent Timmerman
- Department of Molecular Genetics, VIB and University of Antwerp, 2610 Antwerpen, Belgium
- Laboratory of Neurogenetics, Institute Born-Bunge, 2610 Antwerpen, Belgium
- Peripheral Neuropathy Group, VIB Department of Molecular Genetics, University of Antwerp, Universiteitsplein 1, 2610 Antwerpen, Belgium
| |
Collapse
|